Single cell analyses of bone marrow immune microenvironment in RRMM subjects treated with MEK1/2 inhibitors reveal IRF1-mediated IFN/PDL1 signaling axes

Chaitanya Acharya

Single-cell RNA-sequencing of 6 million tumor and immune cells in patients with plasma cell premalignancy unveils co-regulation of disease progression by tumor biology and immune dysregulation

Romanos Sklavenitis-Pistofidis

Efficacy and safety of Isa-KRd induction before response-adapted consolidation in transplant eligible newly diagnosed multiple myeloma: an interim analysis of the IFM2020-02 MIDAS study.

Aurore Perrot

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience With Updated Follow-up

Surbhi Sidana

Importance of Patient-Reported Symptoms and Health-Related Quality of Life for drug approval in multiple myeloma

Michel Delforge, MD, PhD

Prevention of infections during treatment with bispecific antibodies and CAR T cells in multiple myeloma​

Heinz Ludwig, MD

Development of an academic CAR-T in MM : the Spanish experience

Carlos Fernández de Larrea

Drug access in Brazil; equity actions between Public and Private Health Systems

Angelo Maiolino, MD, PhD

Optimal therapy for young patients with high-risk disease: the European point of view

Katja Weisel, MD

Do we need PET-CT to assess response in multiple myeloma?

Elena Zamagni, MD, PhD

Findings from the Australian and New Zealand myeloma and related diseases registry​

Andrew Spencer, MD, PhD

Resistance to bispecific antibodies

Paola Neri, MD, PhD

Role of tandem autologous stem cell transplantation for the treatment of multiple myeloma

Mohamad Mohty, MD, PhD

Ongoing clinical trials from the Nordic Group

Fredrik Schjesvold, MD, PhD

Frontline Therapy for transplant ineligible patients: the European perspective

Xavier Leleu, MD, PhD